- Home
- Home
- ADME PK
- ADME PK
- In Vitro Metabolism
- In Vitro Metabolism overview
- Reaction Phenotyping
- Cytochrome P450 Induction
- Relative Induction Score
- Cytochrome P450 (CYP) Inhibition (IC50)
- Cytochrome P450 Inhibition (Ki)
- Hepatocyte Stability
- Low Clearance HµREL Co-culture
- Low Clearance Hepatocyte Stability
- Hepatic Uptake Assay
- Metabolite Profiling and Identification
- Plasma Stability
- Microsomal Stability
- Microsomal Binding
- S9 Stability
- Time Dependent CYP Inhibition (single point)
- Time Dependent CYP Inhibition (IC50 shift)
- Time Dependent CYP Inhibition (kinact/KI )
- PXR and AhR Nuclear Receptor Activation
- UGT Inhibition
- In Vitro Permeability and Drug Transporter Services
- In Vitro Permeability and Drug Transporter Services overview
- PAMPA
- Caco-2 Permeability
- MDCK-MDR1 Permeability
- P-gp Substrate Identification
- BCRP Substrate Identification
- Human SLC Transporter Substrate Identification
- Human MRP Transporter Substrate Identification
- Preclinical Hepatic Oatp Substrate Identification
- P-glycoprotein Inhibition Service
- BCRP Inhibition Service
- Human SLC Transporter Inhibition
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Preclinical Hepatic Oatp Transporter Inhibition
- Non-CYP Mediated Metabolism
- Protein Binding
- Bioanalysis
- High Throughput ADME
- DDI Packages
- Prodrug Services
- Toxicology
- Toxicology
- 3D Microtissue Models
- Mitochondrial Toxicity
- Multiparametric Toxicity
- Immunotoxicology
- Genotoxicity
- Hepatotoxicity and Drug-induced Liver Injury (DILI)
- Hepatotoxicity and Drug-induced Liver Injury (DILI) overview
- CellCiphr® Premier
- Genotoxicity
- Transcriptomics Services
- Mitochondrial Toxicity
- Cytochrome P450 Time Dependent Inhibition (IC50 Shift)
- Reactive Metabolite Assessment
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Lysosomal Trapping
- Drug Induced Phospholipidosis & Steatosis Assay
- Cytotoxicity Screening Panel
- 3D Hepatotoxicity Assay using HepaRG Spheroids
- Mechanistic Toxicity
- Mechanistic Toxicity overview
- Cell Stress Panel
- Apoptosis and Necrosis Assay (Flow Cytometry)
- Phospholipidosis and Steatosis
- Lysosomal Trapping
- Hemolysis
- DILIsym collaboration
- Reactive Metabolite
- Toxicological Gene Regulation
- Cell Viability
- KeratinoSens™ Skin Sensitization
- Androgen Receptor Modulation
- Phototoxicity
- Nephrotoxicity
- Neurotoxicity
- Cardiotoxicity
- Drug-Drug Interactions
- Non-GLP Exploratory Toxicology
- Customized Toxicology Service
- In Silico
- Physicochemical Profiling
- About
- Services
- Services
- ADME PK
- ADME PK
- In Vitro Metabolism
- In Vitro Metabolism overview
- Reaction Phenotyping
- Cytochrome P450 Induction
- Relative Induction Score
- Cytochrome P450 (CYP) Inhibition (IC50)
- Cytochrome P450 Inhibition (Ki)
- Hepatocyte Stability
- Low Clearance HµREL Co-culture
- Low Clearance Hepatocyte Stability
- Hepatic Uptake Assay
- Metabolite Profiling and Identification
- Plasma Stability
- Microsomal Stability
- Microsomal Binding
- S9 Stability
- Time Dependent CYP Inhibition (single point)
- Time Dependent CYP Inhibition (IC50 shift)
- Time Dependent CYP Inhibition (kinact/KI )
- PXR and AhR Nuclear Receptor Activation
- UGT Inhibition
- In Vitro Permeability and Drug Transporter Services
- In Vitro Permeability and Drug Transporter Services overview
- PAMPA
- Caco-2 Permeability
- MDCK-MDR1 Permeability
- P-gp Substrate Identification
- BCRP Substrate Identification
- Human SLC Transporter Substrate Identification
- Human MRP Transporter Substrate Identification
- Preclinical Hepatic Oatp Substrate Identification
- P-glycoprotein Inhibition Service
- BCRP Inhibition Service
- Human SLC Transporter Inhibition
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Preclinical Hepatic Oatp Transporter Inhibition
- Non-CYP Mediated Metabolism
- Protein Binding
- Bioanalysis
- High Throughput ADME
- DDI Packages
- Prodrug Services
- Toxicology
- Toxicology
- 3D Microtissue Models
- Mitochondrial Toxicity
- Multiparametric Toxicity
- Immunotoxicology
- Genotoxicity
- Hepatotoxicity and Drug-induced Liver Injury (DILI)
- Hepatotoxicity and Drug-induced Liver Injury (DILI) overview
- CellCiphr® Premier
- Genotoxicity
- Transcriptomics Services
- Mitochondrial Toxicity
- Cytochrome P450 Time Dependent Inhibition (IC50 Shift)
- Reactive Metabolite Assessment
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Lysosomal Trapping
- Drug Induced Phospholipidosis & Steatosis Assay
- Cytotoxicity Screening Panel
- 3D Hepatotoxicity Assay using HepaRG Spheroids
- Mechanistic Toxicity
- Mechanistic Toxicity overview
- Cell Stress Panel
- Apoptosis and Necrosis Assay (Flow Cytometry)
- Phospholipidosis and Steatosis
- Lysosomal Trapping
- Hemolysis
- DILIsym collaboration
- Reactive Metabolite
- Toxicological Gene Regulation
- Cell Viability
- KeratinoSens™ Skin Sensitization
- Androgen Receptor Modulation
- Phototoxicity
- Nephrotoxicity
- Neurotoxicity
- Cardiotoxicity
- Drug-Drug Interactions
- Non-GLP Exploratory Toxicology
- Customized Toxicology Service
- In Silico
- Physicochemical Profiling
- Unique Technologies
- Publications/Guides
- Events
- News
- Blog
- Investor
- Contact
- Careers
Home > Company News > Circular to Shareholders & Explanatory Statement under section 897 of the Companies Act 2006-Notice of Court & General Meetings
Circular to Shareholders & Explanatory Statement under section 897 of the Companies Act 2006-Notice of Court & General Meetings
November 4th 2016
Close
Contact us to discuss your ADME Tox issues or request a quote
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com
or fill out the form below:
Close
Close
Download file
Close